

TEST CHANGE

Myeloid Malignancies Mutation Panel by Next Generation Sequencing

Lavender (EDTA), gGreen (sodium heparin), <u>bone marrow</u> Bone Marrow (EDTA), or <u>bone marrowBone Marrow</u> (sodium heparin). Fresh-frozen Tissue.
Whole Blood or Bone Marrow: Transport 3 mL. (Min: 1.0 mL for bone marrow, 1.5 mL for whole blood) Fresh-frozen Tissue: Transport 5 mg fresh-frozen tissue. (Min: 5 mg) Separate specimens must be submitted when multiple tests are ordered
Whole Blood or Bone Marrow: Refrigerated. <u>Fresh-frozen</u> Tissue: Frozen.
Serum, plasma, grossly hemolyzed specimens, buccal brush or swab, FFPE tissue.
Whole Blood or Bone Marrow: Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable - Fresh-frozen Tissue: Ambient: Unacceptable; Refrigerated: Unacceptable; Frozen: 1 month
Massively Parallel Sequencing
Varies
12-14 days
Genes tested: ANKRD26; ASXL1; ASXL2; BCOR; BCORL1; BRAF; CALR; CBL; CBLB; CEBPA; CSF3R; CUX1*; DDX41; DNMT1*; DNMT3A; ELANE; ETNK1; ETV6; EZH2; FBXW7; FLT3; GATA1; GATA2; GNAS; HNRNPK; IDH1; IDH2; IL7R; JAK1; JAK2; JAK3; KDM6A*; KIT; KMT2A; KRAS; LUC7L2; MPL; NOTCH1; NPM1*; NRAS; NSD1; PHF6; PIGA; PPM1D; PRPF40B; PRPF8; PTPN11; RAD21; RUNX1; SAMD9; SAMD9L; SETBP1; SF3B1; SH2B3; SMC1A; SMC3; SRSF2; STAG2; STAT3; STAT5B*; SUZ12*; TET2; TP53; U2AF1; U2AF2; UBA1;
WT1; ZRSR2 *One or more exons are not covered by sequencing for the indicated gene; see Additional Technical Information.



New York DOH Approval Status:

Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.

Interpretive Data:

Refer to report. Refer to report.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

Reference Interval:

By report